Background and rationale for radiotherapy in early-stage Hodgkin lymphoma

TY - CHAP

T1 - Background and rationale for radiotherapy in early-stage Hodgkin lymphoma

AU - Specht, Lena

AU - Ng, Andrea

PY - 2011

Y1 - 2011

N2 - Radiotherapy for early-stage Hodgkin lymphoma (HL) has undergone substantial transformation over the last several decades, from being the sole treatment modality using large treatment fields to adjuvant local therapy directed to limited site(s) after systemic therapy. Radiation doses and field sizes have decreased, leading to dramatic reductions in risks of long-term complications from radiotherapy compared with the treatments of the past. Meta-analysis of randomized trials of chemotherapy with or without radiotherapy show a highly significant advantage for inclusion of radiotherapy both with regard to tumor control and with regard to overall survival (OS). There is as yet no documented method to select patients for treatment without radiotherapy, not even by positron emission tomography (PET) response. The treatment of choice for early-stage HL is abbreviated chemotherapy followed by limited radiation therapy. Continued advances in radiation therapy technology will further improve targeting while sparing normal tissues.

AB - Radiotherapy for early-stage Hodgkin lymphoma (HL) has undergone substantial transformation over the last several decades, from being the sole treatment modality using large treatment fields to adjuvant local therapy directed to limited site(s) after systemic therapy. Radiation doses and field sizes have decreased, leading to dramatic reductions in risks of long-term complications from radiotherapy compared with the treatments of the past. Meta-analysis of randomized trials of chemotherapy with or without radiotherapy show a highly significant advantage for inclusion of radiotherapy both with regard to tumor control and with regard to overall survival (OS). There is as yet no documented method to select patients for treatment without radiotherapy, not even by positron emission tomography (PET) response. The treatment of choice for early-stage HL is abbreviated chemotherapy followed by limited radiation therapy. Continued advances in radiation therapy technology will further improve targeting while sparing normal tissues.

U2 - 10.1007/978-3-540-78944-4

DO - 10.1007/978-3-540-78944-4

M3 - Book chapter

SN - 978-3-540-78455-5

SP - 7

EP - 20

BT - Radiotherapy for Hodgkin lymphoma

A2 - Specht, Lena

A2 - Yahalom, Joachim

PB - Springer

CY - Berlin

ER -